TABLE 2.

Categories of functional clusters, number and characteristics of altered genes, potential correlations with therapies, and list of key findings in the patient

Categories	Number of genes	Genes	Key findings
Key genes of lung cancer	17	EGFR, ALK, RET, ROS1, BRAF, HER2, PIK3CA, c‐MET, FGFR1, KRAS, TP53, PD‐1, BIM, MEK1, ALK, VEGFR2, VEGF	Three key gene mutations in lung cancer were detected
Immunotherapy	53	5	No mutations were detected
Tumor signaling pathway	–	–	Four abnormal tumor signaling pathways were detected
Family heredity	58	–	No mutations were detected
Others	25750	–	39 somatic cell mutations were detected
PD1/PDL1 signaling pathway	IFN signaling pathway JAK signaling pathway PD1/PDL1		No mutations were detected. Immunotherapy may have good effects on the patient.
MSI	Lynch syndrome–related genes (MSH2, MSH6, MLH1, PMS2)		No mutations were detected. Immunotherapy may not have good effects on the patient.
TMB	<100		Low TMB. Immunotherapy may not have good effects on the patient.

Abbreviations: ALK, anaplastic lymphoma kinase; BIM, BCL2 like 11; BRAF, B‐Raf proto‐oncogene, serine/theronine kinase; c‐MET, MET proto‐oncogene, receptor tyrosine kinase; EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth factor receptor 1; HER2, human epidermal growth factor receptor‐2; IFN, Interferon; JAK, Janus kinase; KRAS, KRAS proto‐oncogene GTPase; MEK1, MAP kinase/ERK kinase 1; MLH1, mutL homolog 1; MSH2, mutS homolog 2; MSH6, mutS homolog 6; MSI, microsatellite instability.; PD‐1, programmed cell death 1; PIK3CA, phosphatidylinositol 3‐kinase catalytic alpha polypeptide gene; PMS2, PMS1 homolog 2, mismatch repair system component; RET, Ret proto‐oncogene; ROS1, ROS proto‐oncogene1 receptor tyrosine kinase; TMB, tumor mutation burden; TP53, tumor protein p53; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor